<DOC>
	<DOCNO>NCT00342134</DOCNO>
	<brief_summary>Our goal elucidation mechanism action autologous hematopoietic stem cell transplant ( HSCT ) immunoablation high-dose cyclophosphamide multiple sclerosis ( MS ) . The molecular pathogenesis multiple sclerosis poorly understood although T-cell mediate immune destruction myelin think important element . We hypothesize , result previous study suggest , radical immuno-ablation characterize profound T cell depletion arrest progression disease . Patients MS poor prognosis base rate progression refractoriness approve treatment ( interferon-beta , glatiramer acetate ) enrol clinical trial collaborate institution ( NWU-Dr. R. Burt ; Dr. D Kerr , JHU ) receive either immune ablation cyclophosphamide antibody Campath-1 follow reconstitution autologous peripheral blood stem cell , procedure similar autologous bone marrow transplantation , high-dose cyclophosphamide treatment without stem cell rescue . While overall treatment-related mortality worldwide approximately 10 % , collaborate institution investigator outstanding safety record perform procedure fatal adverse event transplant 30 transplant previously aggressive regimen one use . The underlying rationale treatment immuno-ablation could eliminate myelin-reactive T cell , disease-susceptible individual , may activate previous exposure environmental agent acquire mechanism immune dysregulation . In propose study plan address whether HSCT immunoablation without stem cell rescue act beneficially MS via eradication myelin-reactive T cell reconstitution functional non-autoimmune immune repertoire . To achieve goal , compare peripheral blood T cell reactivity myelin antigen treatment 34 patient MS . In parallel , identify potential disease-mediating cell recognize myelin antigen , search clonally expand cell blood MS patient treatment employ molecular analysis T cell receptor repertoire . Expanded T cell clone track post-transplant follow-up patient . If eradication certain clonotypes result immuno-ablation correlate disease remission , attempt isolate cell culture pre-treatment sample determine specificity use combinatorial peptide library . We would use approach case reappearance new clonal expansion concomitant disease relapse . We combine study broader , unbiased approach employ microarray technology identify potential change gene expression profile . This approach may also lead identification novel therapeutic target pharmacological treatment .</brief_summary>
	<brief_title>Immunological Mechanisms Hematopoietic Stem Cell Transplantation Multiple Sclerosis</brief_title>
	<detailed_description>Our goal elucidation mechanism action autologous hematopoietic stem cell transplant ( HSCT ) immunoablation high-dose cyclophosphamide multiple sclerosis ( MS ) . The molecular pathogenesis multiple sclerosis poorly understood although T-cell mediate immune destruction myelin think important element . We hypothesize , result previous study suggest , radical immuno-ablation characterize profound T cell depletion arrest progression disease . Patients MS poor prognosis base rate progression refractoriness approve treatment ( interferon-beta , glatiramer acetate ) enrol clinical trial collaborate institution ( NWU-Dr. R. Burt ; Dr. D Kerr , JHU ) receive either immune ablation cyclophosphamide antibody Campath-1 follow reconstitution autologous peripheral blood stem cell , procedure similar autologous bone marrow transplantation , high-dose cyclophosphamide treatment without stem cell rescue . While overall treatment-related mortality worldwide approximately 10 % , collaborate institution investigator outstanding safety record perform procedure fatal adverse event transplant 30 transplant previously aggressive regimen one use . The underlying rationale treatment immuno-ablation could eliminate myelin-reactive T cell , disease-susceptible individual , may activate previous exposure environmental agent acquire mechanism immune dysregulation . In propose study plan address whether HSCT immunoablation without stem cell rescue act beneficially MS via eradication myelin-reactive T cell reconstitution functional non-autoimmune immune repertoire . To achieve goal , compare peripheral blood T cell reactivity myelin antigen treatment 34 patient MS . In parallel , identify potential disease-mediating cell recognize myelin antigen , search clonally expand cell blood MS patient treatment employ molecular analysis T cell receptor repertoire . Expanded T cell clone track post-transplant follow-up patient . If eradication certain clonotypes result immuno-ablation correlate disease remission , attempt isolate cell culture pre-treatment sample determine specificity use combinatorial peptide library . We would use approach case reappearance new clonal expansion concomitant disease relapse . We combine study broader , unbiased approach employ microarray technology identify potential change gene expression profile . This approach may also lead identification novel therapeutic target pharmacological treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>INCLUSION CRITERIA : Males female age 18 70 year , inclusive . Diagnosis clinically definite MS accord McDonald Criteria . Must conventional immunomodulatory treatment ( interferon beta glatiramer acetate least 3 month OR tolerate conventional treatment OR refuse start conventional treatment ) . Two total gadolinium enhance lesion two pretreatment MRI scan screen enrollment OR one large enhance lesion measure least 1 cm refractory treatment IV steroid two pretreatment scan . Subject must EDSS range 1.5 6.5 . Subject must least one clinical exacerbation last year , must occur Avonex , Betaseron , Copaxone Rebif therapy least 3 month . This apply subject refuse start conventional therapy . Subject must sustain ( great equal 3 month ) increase great equal 1.0 EDSS ( historical estimate allow ) 1.5 5.5 great equal 0.5 5.5 6.5 precede year . Written inform consent prior test protocol , include screen test evaluation consider part subject 's routine care . Women childbearing potential negative pregnancy test prior entry study . EXCLUSION CRITERIA : Any risk pregnancy ALL female patient must effective mean birth control infertile due hysterectomy , fallopian tube surgery , premature menopause . Cardiac ejection fraction le 45 percent . Serum creatinine great 2.0 . Patients preterminal moribund . Bilirubin great 2.0 , transaminase great 2 time normal . Patients EDSS le 1.5 great 6.5 . Patients pacemaker implant get serial MRIs . Patients active infection infection resolve . Patients WBC count less 3000 cell per microliter , platelets less 100,000 cell per microliter untransfused hemoglobin le 10 gram per deciliter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 4, 2011</verification_date>
	<keyword>Demyelination</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>